According to Fortune Business Insights, the global immunoassay market size was valued at USD 26.80 billion in 2025 and is projected to grow from USD 28.81 billion in 2026 to USD 51.80 billion by 2034, exhibiting a CAGR of 7.6% during the forecast period. North America dominated the market with a 33.76% share in 2025. Immunoassays are widely used to detect and quantify antibodies, hormones, antigens, proteins, drugs, and disease-associated biomarkers across clinical diagnostics, drug development, and research applications.

Immunoassay Market Overview

Immunoassay refers to laboratory testing methods that use antigen-antibody reactions to identify and measure specific substances in biological samples. These tests are extensively used for infectious disease testing, endocrinology, cardiology, oncology, autoimmune and allergy testing, neurology, reproductive health, drug development, and academic research.

The growth of the immunoassay market is being supported by the increasing prevalence of chronic diseases, rising diagnostic testing volumes, growing adoption of biomarker-based diagnosis, and the expansion of automated laboratory systems. The market includes instruments, reagents and kits, as well as consumables and accessories used throughout the testing process.

Request a Free Sample: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/immunoassay-market-104464

Key Immunoassay Market Trends

Increasing Integration of Automation and Artificial Intelligence

The integration of automation and artificial intelligence (AI) is emerging as a significant trend in the immunoassay industry. Automated analyzers can streamline sample handling, reagent dispensing, incubation, detection, and result interpretation, reducing manual intervention and improving laboratory productivity.

AI-enabled systems can additionally support automated quality control, pattern recognition, predictive maintenance, and interpretation of complex assay results. Advanced algorithms are also being incorporated into digital immunoassay and multiplex testing platforms to improve biomarker quantification and analytical performance.

Immunoassay Market Growth Drivers

Increasing Adoption of Biomarker-Based Diagnosis and Disease Monitoring

The growing use of biomarker-based diagnosis and disease monitoring is a major factor supporting market growth. Immunoassays enable rapid and repeat testing for infections, thyroid disorders, cardiac injury, cancer markers, fertility conditions, autoimmune diseases, and neurological disorders.

Healthcare systems are increasingly emphasizing earlier diagnosis and longitudinal disease monitoring. This trend is contributing to higher immunoassay testing volumes across hospitals, reference laboratories, and outpatient facilities.

Growing Adoption of Automated and High-Throughput Platforms

The adoption of automated and high-throughput immunoassay platforms is also supporting market expansion. Automated systems allow laboratories to process larger sample volumes while reducing manual procedures and improving workflow efficiency.

The growing need to manage increasing diagnostic workloads with limited technical staff is encouraging healthcare facilities and laboratories to invest in automated technologies.

Increasing Diagnostic Testing for Chronic and Infectious Diseases

The rising burden of chronic and infectious diseases is increasing demand for diagnostic testing. Immunoassays are used across several disease areas, including infectious diseases, endocrinology, cardiovascular disorders, oncology, autoimmune conditions, reproductive health, and neurological disorders.

Immunoassay Market Restraints

High Instrument, Reagent, and Lifecycle Costs

High capital and operating costs can limit the adoption of advanced immunoassay systems, particularly among smaller laboratories and healthcare facilities in lower-resource markets. Automated systems require investments in instruments, proprietary reagents, calibrators, controls, maintenance, software, trained personnel, and supporting infrastructure.

Regulatory compliance can also increase product development costs because manufacturers need to establish analytical performance, clinical validity, manufacturing consistency, and post-market quality.

Assay Interference and Standardization Challenges

Assay interference, cross-reactivity, matrix effects, calibration differences, heterophile antibodies, and biotin interference can affect immunoassay results. Differences between assays, instruments, laboratories, and patient populations can also create challenges in maintaining comparable results.

Quality control, proficiency testing, verification, and method-comparison studies are therefore important when laboratories introduce new assays. The absence of standardized reference systems for some analytes can further challenge market expansion.

Immunoassay Market Opportunities

Expanding Clinical Utility of Blood-Based Neurological Biomarkers

The growing clinical application of blood-based neurological biomarkers is creating opportunities for immunoassay manufacturers. Conditions such as Alzheimer’s disease, traumatic brain injury, multiple sclerosis, and other neurological disorders have traditionally relied on imaging, cerebrospinal fluid analysis, and specialist assessment.

High-sensitivity automated immunoassays can support the measurement of selected neurological biomarkers in routine laboratory settings. This may facilitate earlier triage, disease monitoring, and patient referral. In April 2026, F. Hoffmann-La Roche Ltd. received CE Mark for its Elecsys NfL blood test for neuroinflammation monitoring in multiple sclerosis.

Immunoassay Market Segmentation Analysis

By Product Type

Based on product type, the market is segmented into instruments, reagents & kits, and consumables & accessories.

The reagents & kits segment accounted for the largest market share in 2025. Immunoassay testing requires recurring consumption of assay-specific reagents, substrates, cartridges, conjugates, coated reaction vessels, and complete assay kits. This recurring demand supports the segment's leading position.

The instruments segment is projected to grow at a CAGR of 7.4% during the forecast period.

By Detection Technology

Based on detection technology, the market is divided into chemiluminescence & electrochemiluminescence immunoassays, colorimetric immunoassays, fluorescence immunoassays, radioimmunoassays, immunoturbidimetric & nephelometric immunoassays, and others.

The chemiluminescence & electrochemiluminescence immunoassays segment held the largest market share in 2025. These technologies offer high analytical sensitivity, a broad measurement range, short turnaround times, and compatibility with automated random-access analyzers.

The segment is projected to account for a 43.3% share in 2026. Meanwhile, the colorimetric immunoassays segment is expected to grow at a CAGR of 6.2% during the forecast period.

By Application

Based on application, the market is divided into clinical diagnostics and non-clinical applications.

The clinical diagnostics segment dominated the market in 2025. Immunoassays are extensively used for routine diagnosis, screening, emergency assessment, and chronic disease monitoring. Major testing areas include infectious diseases, thyroid and metabolic disorders, cardiac conditions, cancer biomarkers, autoimmune diseases, allergies, fertility, pregnancy, and neurological disorders.

The clinical diagnostics segment is estimated to account for 87.8% of the market in 2026. The non-clinical applications segment, which includes drug discovery & development and academic & translational research, is anticipated to grow at a rate of 8.9% during the forecast period.

By End User

Based on end user, the market is segmented into hospitals & clinics, independent & reference laboratories, pharmaceutical & biotechnology companies, academic & research institutes, home healthcare, and others.

Hospitals & clinics dominated the market in 2025. These healthcare facilities conduct substantial volumes of routine, emergency, inpatient, and outpatient immunoassay testing. The segment is expected to hold a 62.3% share in 2026.

The independent & reference laboratories segment is projected to grow at a CAGR of 8.0% during the forecast period.

Immunoassay Market Regional Analysis

North America

North America held the largest share of the global immunoassay market in 2025, accounting for 33.76%. The regional market was valued at USD 9.05 billion in 2025. Advanced clinical laboratory infrastructure, high adoption of automated testing platforms, favorable reimbursement conditions, and substantial diagnostic testing volumes are supporting regional growth.

The U.S. immunoassay market is anticipated to reach USD 8.89 billion in 2026, representing approximately 30.9% of the global market.

Europe

Europe represents an important market for immunoassay technologies, supported by established healthcare systems, advanced laboratory infrastructure, and continued development of diagnostic technologies. Product launches and regulatory approvals for new immunoassays are also contributing to the development of the regional market.

Asia Pacific

Asia Pacific is expected to witness increasing demand for immunoassay products as healthcare infrastructure and diagnostic capabilities expand. Growing testing volumes and greater access to laboratory automation are supporting opportunities across the region.

Latin America

The Latin American market is supported by increasing demand for diagnostic testing and the gradual expansion of healthcare and laboratory infrastructure. The growing need for disease screening and monitoring is expected to create additional opportunities for immunoassay products.

Middle East & Africa

The Middle East & Africa market is benefiting from efforts to improve healthcare infrastructure and diagnostic accessibility. The expansion of laboratory capabilities and increasing healthcare investment are expected to support immunoassay adoption.

Key Industry Developments

Several companies have introduced new products and received regulatory approvals to strengthen their immunoassay portfolios. In May 2026, Hoffmann-La Roche Ltd. received CE Mark for Elecsys pTau217, a blood-based immunoassay intended to rule in or rule out Alzheimer’s amyloid pathology.

In April 2026, Beckman Coulter, Inc. received CE Mark under IVDR for the Access MeMed BV immunoassay, which differentiates bacterial from viral infections. In March 2026, Siemens Healthineers AG launched automated Atellica IM pTau217 and brain-derived tau assays for neurological and Alzheimer’s disease research.

Earlier developments included Fujirebio's launch of the Lumipulse G pTau217 CSF automated chemiluminescent enzyme immunoassay in January 2026 and Revvity's launch of the IDS i20 fully automated random-access chemiluminescence immunoassay platform in May 2025.

Key Companies in the Immunoassay Market

The major companies operating in the market include:

  • Thermo Fisher Scientific Inc.
  • F. Hoffmann-La Roche Ltd.
  • Abbott
  • Beckman Coulter, Inc.
  • Bio-Rad Laboratories, Inc.
  • QuidelOrtho Corporation
  • DiaSorin S.p.A.
  • Revvity
  • Siemens Healthineers AG
  • Fujirebio

Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Abbott, Beckman Coulter, Inc., and Bio-Rad Laboratories, Inc. held the highest market share in 2025, according to Fortune Business Insights.

Read Report Insights: https://www.fortunebusinessinsights.com/immunoassay-market-104464

Future Outlook for the Immunoassay Market

The global immunoassay market is expected to continue expanding as healthcare providers increase the use of biomarker-based diagnosis, automated testing, and disease monitoring. Technological developments involving AI, laboratory automation, high-throughput analyzers, multiplex testing, and blood-based neurological biomarkers are expected to influence product development.

At the same time, manufacturers and laboratories will need to address costs, assay interference, standardization, regulatory requirements, and result comparability. The combination of increasing diagnostic volumes and technological advances is expected to remain important to the market's development through 2034.

Frequently Asked Questions About the Immunoassay Market

1. How big is the global immunoassay market?

Fortune Business Insights says that the global market value stood at USD 26.80 billion in 2025 and is projected to reach USD 51.80 billion by 2034.

2. What is the CAGR of the immunoassay market?

The market is expected to exhibit a CAGR of 7.6% during the forecast period of 2026-2034.

3. Which segment dominated the immunoassay market by product type?

The reagents & kits segment led the market by product type in 2025, supported by recurring consumption of assay-specific reagents, substrates, cartridges, conjugates, and kits.

4. What are the major trends in the immunoassay market?

The increasing integration of automation and artificial intelligence into immunoassay platforms is a major market trend. Automated systems and AI-enabled software are helping laboratories improve workflow efficiency, quality control, result interpretation, and biomarker quantification.

5. Who are the key players in the immunoassay market?

Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Abbott, Beckman Coulter, Inc., and Bio-Rad Laboratories, Inc. are among the prominent players in the global immunoassay market.

Curious About Japan’s Market? Explore the Latest - immunoassay market- Insights